Cytek Biosciences, Inc.
CTKB
$3.64
$0.041.11%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -84.83% | 75.23% | 114.56% | -137.78% | 9.37% |
| Total Depreciation and Amortization | 17.24% | 13.03% | 9.77% | 1.43% | 36.59% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -7.82% | -190.12% | 26.10% | 44.52% | 39.51% |
| Change in Net Operating Assets | 64.00% | -43.27% | 161.85% | 259.15% | -49.99% |
| Cash from Operations | -103.16% | -79.01% | 411.89% | 317.68% | 38.45% |
| Capital Expenditure | -49.74% | 40.40% | 23.98% | 19.80% | -12.28% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -99.58% | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 297.96% | -302.13% | -133.33% | -26.91% | 95.80% |
| Cash from Investing | 264.27% | -318.24% | -136.66% | -27.53% | 96.59% |
| Total Debt Issued | -50.50% | -- | -- | -- | -- |
| Total Debt Repaid | -992.09% | 0.71% | -1.45% | 1.42% | 4.79% |
| Issuance of Common Stock | -92.29% | -32.11% | -66.67% | -15.04% | 149.26% |
| Repurchase of Common Stock | -7,167.57% | 79.56% | -41.03% | -156.41% | -159.65% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -815.75% | 89.22% | -46.05% | -892.13% | -- |
| Foreign Exchange rate Adjustments | -172.45% | 284.45% | -163.98% | 324.85% | 255.50% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -328.06% | -1,688.55% | -148.67% | 1,132.59% | 100.90% |